When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 16 Mar 2025
Last updated: 08 Mar 2024

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • previous superficial vein thrombosis (SVT), deep vein thrombosis, or pulmonary embolism
  • redness/erythema of overlying skin
  • hot/warm overlying skin
  • painful/tender over affected vein
  • swelling/oedema of surrounding area
  • cord-like mass palpable
  • development of symptoms over hours to days
  • signs/symptoms of concomitant DVT or PE

Other diagnostic factors

  • varicose veins
  • history of thrombophilic disorders
  • autoimmune diseases (e.g., Behcet's and Buerger's disease)
  • recent vein instrumentation (e.g., sclerotherapy)
  • recent vein cannulation and intravenous drug administration
  • low-grade fever
  • pigmentation changes

Risk factors

  • varicose veins
  • thrombophilic disorders
  • autoimmune diseases (e.g., Behcet's and Buerger's disease)
  • prior history of superficial vein thrombosis (SVT)
  • female sex
  • sclerotherapy
  • intravenous catheterisation
  • malignancy
  • pregnancy
  • use of oral contraceptives (OCPs) and hormonal replacement therapy
  • older age
  • history of prior venous thromboembolism (VTE), including deep vein thrombosis and PE
  • obesity
  • prolonged immobilisation (e.g., long-haul air travel)
  • blood type

Diagnostic investigations

Investigations to consider

  • biopsy
  • pulmonary CT angiography
  • ventilation perfusion (VQ) scan
  • conventional pulmonary angiography
  • assessment for malignancy
  • thrombophilia screening

Treatment algorithm

Contributors

Authors

Sherry Scovell, MD, FACS

Vascular and Endovascular Surgeon

Massachusetts General Hospital

Assistant Professor of Surgery, Part Time

Harvard Medical School

Boston

MA

Disclosures

SS is an author for UpToDate, which is compensated. SS declares that she has no conflicts of interest with medical or pharmaceutical companies.

Acknowledgements

Dr Sherry Scovell would like to gratefully acknowledge Professor Vicky Tagalakis, a previous contributor to this topic.

Disclosures

VT has received reimbursement for advisory board work for Servier and Pzifer. Both of these companies are makers of anticoagulants. VT has received an investigator-initiated grant from Sanofi, manufacturer of Enoxaparin.

Peer reviewers

Francois Becker, MD, PhD

Consultant

Division of Angiology and Hemostasis

University Hospital of Geneva

Geneva

Switzerland

Disclosures

FB declares that he has no competing interests.

Michael Bromberg, MD, PhD

Professor of Medicine

Section of Hematology

Director of Hematologic Malignancies

Temple University School of Medicine

Philadelphia

PA

Disclosures

MB declares that he has no competing interests.

Louis Aledort, MD

The Mary Weinfeld Professor of Clinical Research in Hemophilia

Mount Sinai School of Medicine

New York

NY

Disclosures

LA declares that he has no competing interests.

Use of this content is subject to our disclaimer